


FIG E1. Venn diagram illustrating the overlap between differential expressed genes identified in different comparisons. *PN*, Nonlesional skin; *PP*, lesional skin.








FIG E2. The normalized expression of *USP18* and *KRT2* in independent data set of control (CO_healthy), uninvolved skin of psoriatic patients (PSO_nonlesional), lesional skin of psoriatic patients (PSO_lesional), uninvolved skin of atopic dermatitis patients (AD_nonlesional), and lesional skin of atopic dermatitis patients (AD_lesional).



 ${\bf FIG}~{\bf E3}.$ The expression of $\it USP18$ in the knockdown experiments in different cytokine-stimulated conditions.



 $\textbf{FIG E4}. \ \ \text{Normalized expression level of } \textit{USP18} \ \text{under different cytokine stimulations in keratinocytes}.$

TABLE E1. Number of differentially expressed genes when comparing the lesional skin (PP) from baseline vs that from follow-up visits

PP week 0 vs:	Upregulated genes	Downregulated genes	Total differential expressed genes
Week 2	42	109	151
Week 6	508	517	1025
Week 12	961	788	1749

FDR \leq 5% and 2-fold change difference were used as criteria.